Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in sendai virus-based human parainfluenza virus type 3 vaccines

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 5959-5969

  Mason, John N ^a   Elbahesh, Husni ^a   Russell, Charles J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PARAINFLUENZA VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; GENE INSERTION; GENETIC STABILITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; OPEN READING FRAME; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECOMBINANT SENDAI VIRUS; VIRUS ATTENUATION; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GENETIC VECTORS; PARAINFLUENZA VIRUS 3, HUMAN; RATS; RESPIROVIRUS INFECTIONS; SENDAI VIRUS; SIGMODONTINAE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84877337201     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00227-13     Document Type: Article

References (57)

1. Griffin MR, Walker FJ, Iwane MK, Weinberg GA, Staat MA, Erdman DD. 2004. Epidemiology of respiratory infections in young children: insights from the new vaccine surveillance network. Pediatr. Infect. Dis. J. 23:S188 -S192.
2. Counihan ME, Shay DK, Holman RC, Lowther SA, Anderson LJ. 2001. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr. Infect. Dis. J. 20:646-653.
3. Girard MP, Cherian T, Pervikov Y, Kieny MP. 2005. A review of vaccine research and development: human acute respiratory infections. Vaccine 23:5708 -5724.
4. Karron RA, Collins PL. 2005. Parainfluenza viruses, p 1497-1526. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott/The Williams & Wilkins Co, Philadelphia, PA.
5. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. 2001. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98:573-578.
6. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449- 463.
7. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:435- 448.
8. Schmidt AC, Schaap-Nutt A, Bartlett EJ, Schomacker H, Boonyaratanakornkit J, Karron RA, Collins PL. 2011. Progress in the development of human parainfluenza virus vaccines. Expert Rev. Respir. Med. 5:515-526.
9. Stokes A, Tierney EL, Sarris CM, Murphy BR, Hall SL. 1993. The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3). Virus Res. 30:43-52.
10. van Wyke Coelingh KL, Winter CC, Tierney EL, London WT, Murphy BR. 1988. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J. Infect. Dis. 157:655- 662.
11. Durbin AP, Karron RA. 2003. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin. Infect. Dis. 37: 1668-1677.
12. Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, Collins PL, Murphy BR, Skiadopoulos MH. 2000. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J. Virol. 74:8922- 8929.
13. Takimoto T, Hurwitz JL, Zhan X, Krishnamurthy S, Prouser C, Brown B, Coleclough C, Boyd KL, Scroggs RA, Portner A, Slobod KS. 2005. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol. 18:255-266.
14. Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd KL, Scroggs RA, Surman S, Portner A, Slobod KS. 2007. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine 25:8782- 8793.
15. Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, Surman S, Russell CJ, Portner A, Hurwitz JL. 2008. Sendai virus recombinant vaccine expressing hPIV-3HNor F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3, and RSV infections. Vaccine 26:3480 -3488.
16. Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL. 2009. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 27:1848 -1857.
17. Hurwitz JL, Soike KF, Sangster MY, Portner A, Sealy RE, Dawson DH, Coleclough C. 1997. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 15:533-540.
18. Slobod KS, Shenep JL, Lujan-Zilbermann J, Allison K, Brown B, Scroggs RA, Portner A, Coleclough C, Hurwitz JL. 2004. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22:3182-3186.
19. Burke CW, Mason JN, Surman SL, Jones BG, Dalloneau E, Hurwitz JL, Russell CJ. 2011. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. 7:e1002134. doi:10.1371/journal.ppat.1002134.
20. Krunkosky TM, Fischer BM, Martin LD, Jones N, Akley NJ, Adler KB. 2000. Effects of TNF-alpha on expression of ICAM-1 in human airway epithelial cells in vitro: signaling pathways controlling surface and gene expression. Am. J. Respir. Cell Mol. Biol. 22:685- 692.
21. Fuerst TR, Niles EG, Studier FW, Moss B. 1986. Eukaryotic transientexpression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 83: 8122-8126.
22. Luque LE, Russell CJ. 2007. Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein. J. Virol. 81:3130 -3141.
23. Tokusumi T, Iida A, Hirata T, Kato A, Nagai Y, Hasegawa M. 2002. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res. 86:33-38.
24. Abraham G, Banerjee AK. 1976. Sequential transcription of the genes of vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 73:1504 -1508.
25. Ball LA, White CN. 1976. Order of transcription of genes of vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 73:442- 446.
26. He B, Lamb RA. 1999. Effect of inserting paramyxovirus simian virus 5 gene junctions at the HN/L gene junction: analysis of accumulation of mRNAs transcribed from rescued viable viruses. J. Virol. 73:6228-6234.
27. Horikami SM, Curran J, Kolakofsky D, Moyer SA. 1992. Complexes of Sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro. J. Virol. 66:4901- 4908.
28. Kolakofsky D, Le Mercier P, Iseni F, Garcin D. 2004. Viral DNA polymerase scanning and the gymnastics of Sendai virus RNA synthesis. Virology 318:463- 473.
29. Collins PL, Hightower LE, Ball LA. 1980. Transcriptional map for Newcastle disease virus. J. Virol. 35:682- 693.
30. Feldmann H, Volchkov VE, Volchkova VA, Stroher U, Klenk HD. 2001. Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol. 82:2839- 2848.
31. Schneemann A, Schneider PA, Kim S, Lipkin WI. 1994. Identification of signal sequences that control transcription of Borna disease virus, a nonsegmented, negative-strand RNA virus. J. Virol. 68:6514-6522.
32. Pattnaik AK, Wertz GW. 1990. Replication and amplification of defective interfering particle RNAs of vesicular stomatitis virus in cells expressing viral proteins from vectors containing cloned cDNAs. J. Virol. 64:2948- 2957.
33. Anderson DE, Messling von, V. 2008. Region between the canine distemper virus M and F genes modulates virulence by controlling fusion protein expression. J. Virol. 82:10510 -10518.
34. Durbin AP, Skiadopoulos MH, McAuliffe JM, Riggs JM, Surman SR, Collins PL, Murphy BR. 2000. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J. Virol. 74:6821- 6831.
35. Agungpriyono DR, Yamaguchi R, Uchida K, Tohya Y, Kato A, Nagai Y, Asakawa M, Tateyama S. 2000. Green fluorescent protein gene insertion of Sendai virus infection in nude mice: possibility as an infection tracer. J. Vet. Med. Sci. 62:223-228.
36. Brownstein DG. 1987. Resistance/susceptibility to lethal Sendai virus infection genetically linked to a mucociliary transport polymorphism. J. Virol. 61:1670 -1671.
37. Brownstein DG, Smith AL, Johnson EA. 1981. Sendai virus infection in genetically resistant and susceptible mice. Am. J. Pathol. 105:156 -163.
38. Faisca P, Anh DB, Desmecht DJ. 2005. Sendai virus-induced alterations in lung structure/function correlate with viral loads and reveal a wide resistance/susceptibility spectrum among mouse strains. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L777-L787.
39. Bousse T, Chambers RL, Scroggs RA, Portner A, Takimoto T. 2006. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res. 121:23-32.
40. Skiadopoulos MH, Surman SR, Riggs JM, Elkins WR, St Claire M, Nishio M, Garcin D, Kolakofsky D, Collins PL, Murphy BR. 2002. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 297:153-160.
41. Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd KL, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS. 2004. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J. Virol. 78:6043- 6047.
42. Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, Takimoto T, Portner A, Hurwitz JL. 2012. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 30:959 -968.
43. Piazza FM, Johnson SA, Darnell ME, Porter DD, Hemming VG, Prince GA. 1993. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection. J. Virol. 67:1503-1510.
44. Murphy BR, Hall SL, Kulkarni AB, Crowe JE, Collins PL, Connors M, Karron RA, Chanock RM. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13-36.
45. Haller AA, Miller T, Mitiku M, Coelingh K. 2000. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J. Virol. 74:11626 -11635.
46. Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR. 2001. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone. Vaccine 19:3620 -3631.
47. Schmidt AC, Wenzke DR, McAuliffe JM, St Claire M, Elkins WR, Murphy BR, Collins PL. 2002. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J. Virol. 76:1089 -1099.
48. Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, Reisinger K, Chandler P, Hilty M, Walker RE, Gomez MM, Losonsky GA. 2008. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 26:6373- 6382.
49. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. 2009. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr. Infect. Dis. J. 28:655- 658.
50. Tompkins SM, Lin Y, Leser GP, Kramer KA, Haas DL, Howerth EW, Xu J, Kennett MJ, Durbin RK, Durbin JE, Tripp R, Lamb RA, He B. 2007. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 362:139 -150.
51. Chen Z, Xu P, Salyards GW, Harvey SB, Rada B, Fu ZF, He B. 2012. Evaluating a parainfluenza virus 5-based vaccine in a host with preexisting immunity against parainfluenza virus 5. PLoS One 7:e50144. doi:10.1371/journal.pone.0050144.
52. Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy BR, Samal SK, Collins PL. 2005. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79:13275-13284.
53. Schröer D, Veits J, Keil G, Römer-Oberdörfer A, Weber S, Mettenleiter TC. 2011. Efficacy of Newcastle disease virus recombinant expressing avian influenza virus H6 hemagglutinin against Newcastle disease and low pathogenic avian influenza in chickens and turkeys. Avian Dis. 55:201- 211.
54. Hu H, Roth JP, Estevez CN, Zsak L, Liu B, Yu Q. 2011. Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroupCas a bivalent vaccine in turkeys. Vaccine 29:8624-8633.
55. Kumar S, Nayak B, Collins PL, Samal SK. 2011. Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens. J. Virol. 85:6521- 6534.
56. Kong D, Wen Z, Su H, Ge J, Chen W, Wang X, Wu C, Yang C, Chen H, Bu Z. 2012. Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology 432:327-335.
57. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL. 2006. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 80:10293- 10306.